期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/ijms23010556
关键词
Alzheimer's disease; combination treatment; anti-A beta immunotherapy; microglial phagocytosis; inflammation; gut microbiota
资金
- Merry Life Biomedical Company [08D4-1NP01]
- Ministry of Science and Technology [109-2320-B-400-009]
- National Health Research Institutes [NP-109-PP03]
Research showed that a combination treatment (anti-Aβ antibody NP106 and curcumin analog TML-6) can more effectively lower Aβ levels, improve behavioral deficits, and normalize gut microbiota, providing a new avenue for developing more effective AD treatments.
Alzheimer's disease (AD) is a progressive neurodegenerative disease with a multifactorial etiology. A multitarget treatment that modulates multifaceted biological functions might be more effective than a single-target approach. Here, the therapeutic efficacy of combination treatment using anti-A beta antibody NP106 and curcumin analog TML-6 versus monotherapy was investigated in an APP/PS1 mouse model of AD. Our data demonstrate that both combination treatment and monotherapy attenuated brain A beta and improved the nesting behavioral deficit to varying degrees. Importantly, the combination treatment group had the lowest A beta levels, and insoluble forms of A beta were reduced most effectively. The nesting performance of APP/PS1 mice receiving combination treatment was better than that of other APP/PS1 groups. Further findings indicate that enhanced microglial A beta phagocytosis and lower levels of proinflammatory cytokines were concurrent with the aforementioned effects of NP106 in combination with TML-6. Intriguingly, combination treatment also normalized the gut microbiota of APP/PS1 mice to levels resembling the wild-type control. Taken together, combination treatment outperformed NP106 or TML-6 monotherapy in ameliorating A beta pathology and the nesting behavioral deficit in APP/PS1 mice. The superior effect might result from a more potent modulation of microglial function, cerebral inflammation, and the gut microbiota. This innovative treatment paradigm confers a new avenue to develop more efficacious AD treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据